论文部分内容阅读
背景国外已有多项研究证实曲妥珠单抗联合化疗治疗晚期乳腺癌疗效优于单独应用。中国乳腺癌患者与国外乳腺癌患者相比有不同的发病和临床特征。目的观察曲妥珠单抗联合化疗治疗晚期乳腺癌的疗效和毒性。方法 2001年2月至2006年2月期间我院内科以曲妥珠单抗单药以及曲妥珠单抗联合化疗治疗乳腺癌患者34例,中位化疗周期数为3个周期(1～7)。曲妥珠单抗中位用药时间为14周(2～128)。结果可评价疗效和毒性34例,完全缓解3例,部分缓解7例,稳定15例,病变进展9例,总有效率29.4%,中位疾病进展时间为7个月,一线治疗的有效率为38.4%,临床获益率84.6%。二线及三线治疗的有效率为23.1%,临床获益率为53.8%。结论曲妥珠单抗联合化疗是治疗人表皮生长因子受体2过表达晚期乳腺癌较好的治疗方法。
Background A number of studies abroad have confirmed that trastuzumab combined with chemotherapy is superior to single use in the treatment of advanced breast cancer. Chinese breast cancer patients compared with foreign breast cancer patients have different incidence and clinical features. Objective To observe the efficacy and toxicity of trastuzumab combined with chemotherapy in the treatment of advanced breast cancer. Methods From February 2001 to February 2006, 34 cases of breast cancer were treated with trastuzumab monotherapy and trastuzumab combined with chemotherapy in our department. The median cycle of chemotherapy was 3 cycles (1-7 months) ). Trastuzumab median medication for 14 weeks (2 ~ 128). Results The curative effect and toxicity were evaluated in 34 cases, complete remission in 3 cases, partial remission in 7 cases, stable in 15 cases, pathological changes in 9 cases, the total effective rate was 29.4%, the median disease progression time was 7 months. The first-line treatment was 38.4%, the clinical benefit rate was 84.6%. The effective rate of second-line and third-line treatment was 23.1%, and the clinical benefit rate was 53.8%. Conclusion Trastuzumab combined with chemotherapy is a good treatment for advanced human breast cancer with overexpression of epidermal growth factor receptor 2.